Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Taro Pharmaceutical Industries Ltd.    TARO   IL0010827181

TARO PHARMACEUTICAL INDUSTRIES LTD. (TARO)
Mes dernières consult.
Most popular
  Report  
Real-time Quote. Real-time Cboe BZX - 06/22 06:32:16 pm
118.075 USD   -0.66%
05:20pTARO PHARMACEUT : Annual Report on Form 20-F Available
BU
05/21TARO PHARMACEUT : Provides Results for Year Ended March 31, 2018
AQ
05/18TARO : Fiscal 4Q Earnings Snapshot
AQ
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Taro Pharmaceutical Industries Ltd. : Taro Rejects IsZo's FY Q2 Under Reporting Allegation as Untrue and Irresponsible

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/08/2012 | 11:25pm CEST

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") announced today that it delivered a letter to one of its shareholders IsZo Capital Management LP ("IsZo") in response to IsZo's letter to Taro's Special Committee of the Board of Directors dated November 5, 2012. The full text of the letter is set forth below:

Re: Taro Rejects IsZo's FY Q2 Under Reporting Allegation as Untrue and Irresponsible

Dear Mr. Sheehy,

We at Taro are very appreciative of our shareholders' communications. More recently, our ability to respond to certain inquiries has been limited in light of the pending merger between Taro and Sun Pharma and the related shareholder meeting scheduled December 6, 2012. Rather, our management team's primary focus continues to be on Taro's core business, the performance of which speaks for itself.

Without responding to your many unfounded allegations over the past few months, I feel compelled to publicly correct one of your most recent statements. In your November 5th letter and corresponding press release, you contend that Taro is "gaming its reserves." Your allegation is simply untrue and your comment is, at a minimum, irresponsible to your fellow Taro shareholders.

As a NYSE listed company, Taro takes its financial accounting and reporting obligations very seriously. Although our quarterly financial reporting is presented on an unaudited basis, the accounting methodologies used in estimating our reserves are "consistently applied" quarter to quarter, in conformity with U.S. GAAP. Over the last couple of years, at the request of our Board and Audit Committee, we have taken an extra step by having our independent auditors perform certain "agreed upon procedures" on our financial statements focusing on specific areas, including reserves, prior to issuing our quarterly releases, including that for the quarter ended September 30, 2012.

Given your broad industry knowledge, you undoubtedly appreciate that, while IMS data is useful to the industry for general U.S. market intelligence and a general understanding of long term, product trends, it is not reliable (or prepared) for consolidated financial reporting analysis as you propose.

Finally, I recognize your excitement for Taro as expressed in your letter. I believe that all Taro shareholders have benefited tremendously at what the new management team, under the leadership of Mr. Shanghvi and, subsequently, Mr. Sundaram, have accomplished since the change in control in September 2010.

Sincerely,

/s/ Jim Kedrowski

Jim Kedrowski
Interim Chief Executive Officer

************************

About Taro

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com.

Taro Pharmaceutical Industries Ltd.
William J. Coote, 914-345-9001
VP, Treasurer
[email protected]


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TARO PHARMACEUTICAL INDUST
05:20pTARO PHARMACEUTICAL INDUSTRIES : Annual Report on Form 20-F Available
BU
05/24Crescita’s US Prescription Product is “Launching Shortly,” ..
AQ
05/21TARO PHARMACEUTICAL INDUSTRIES : Provides Results for Year Ended March 31, 2018
AQ
05/18TARO PHARMACEUTICAL INDUSTRIES LTD. : to Host Earnings Call
AC
05/18TARO : Fiscal 4Q Earnings Snapshot
AQ
05/17TARO PHARMACEUTICAL INDUSTRIES : Provides Results for Year Ended March 31, 2018
BU
05/13TARO PHARMACEUTICAL INDUSTRIES : to Announce Full Year Results on May 17, 2018
AQ
05/11TARO PHARMACEUTICAL INDUSTRIES : to Announce Full Year Results on May 17, 2018
BU
03/29TARO PHARMACEUTICAL INDUSTRIES : Crescita Announces Launch of Pliaglis in U.S.
PR
02/14TARO PHARMACEUTICAL INDUSTRIES : Provides Results for December 31, 2017
AQ
More news
News from SeekingAlpha
05/18Taro Pharmaceutical's (TARO) CEO Uday Baldota on Q4 2018 Results - Earnings C.. 
05/18More on Taro Pharmaceutical Q4 results 
05/17Taro Pharmaceutical reports Q4 results 
05/08The Acquirer's Portfolio - Large Cap Q2 Update 
03/12Premarket analyst action - healthcare 
Financials ($)
Sales 2019 729 M
EBIT 2019 384 M
Net income 2019 378 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 13,46
P/E ratio 2020 10,57
Capi. / Sales 2019 6,59x
Capi. / Sales 2020 5,84x
Capitalization 4 806 M
Chart TARO PHARMACEUTICAL INDUST
Duration : Period :
Taro Pharmaceutical Indust Technical Analysis Chart | TARO | IL0010827181 | 4-Traders
Technical analysis trends TARO PHARMACEUTICAL INDUST
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 130 $
Spread / Average Target 9,4%
EPS Revisions
Managers
NameTitle
Uday Vijaykumar Baldota Chief Executive Officer & Director
Dilip Shantilal Shanghvi Chairman
Itamar Karsenti Vice President & Operations Head-Haifa
Mariano Balaguer VP, Chief Financial & Accounting Officer
Avi Avramoff Global Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
TARO PHARMACEUTICAL INDUSTRIES LTD.14.46%4 806
JOHNSON & JOHNSON-12.27%327 330
PFIZER0.00%213 275
NOVARTIS-10.87%189 575
ROCHE HOLDING LTD.-12.58%188 417
MERCK AND COMPANY8.90%164 862